Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1974 1
1991 1
2010 5
2011 1
2012 6
2013 6
2014 7
2015 3
2016 4
2017 1
2018 1
2019 1
2021 3
2022 2
2023 2
2024 3
2025 3
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean nagamori e[au] (52 results)?
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.
Sato S, Shoji T, Jo A, Otsuka H, Abe M, Tatsuki S, Chiba Y, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T. Sato S, et al. Among authors: takatori e. Cancers (Basel). 2024 Jul 15;16(14):2545. doi: 10.3390/cancers16142545. Cancers (Basel). 2024. PMID: 39061184 Free PMC article. Review.
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Abe M, Shoji T, Chiba Y, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Takahashi F, Aida T, Baba T. Abe M, et al. Among authors: takatori e. Anticancer Res. 2023 Mar;43(3):1265-1272. doi: 10.21873/anticanres.16273. Anticancer Res. 2023. PMID: 36854492
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: takatori e. Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10. Int J Clin Oncol. 2022. PMID: 36214925
51 results